Skip to content

Author

V. Frescura

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

LB is progressively shifting from a research tool to a clinical decision-making instrument in HR+/HER2- mBC, and integrated multiparametric LB approaches combining CTCs and ctDNA are crucial to improve prognostic accuracy and clinical decision-making.

V. Frescura, M. Cristofanilli, C. Reduzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.